Navigation Links
Exposure to inflammatory bowel disease drugs could increase leukemia risk
Date:8/6/2014

Bethesda, MD (August 6, 2014) Immunosuppressive drugs called thiopurines have been found to increase the risk of myeloid disorders, such as acute myeloid leukemia and myelodysplastic syndrome, a rare bone marrow disorder, seven-fold among inflammatory bowel disease (IBD) patients. These data were reported in a new study published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association (AGA). Thiopurines are an established treatment for IBD patients, used to reduce inflammation and provide symptom relief.

"In order to make appropriate, informed decisions about thiopurines, patients and providers need to be well-educated about the risks and benefits of this treatment," said study author Laurent Peyrin-Biroulet, MD, PhD, department of hepato-gastroenterology, University Hospital of Nancy-Brabois in France. "According to our research, the risk of myeloid disorders was not increased among the overall IBD population, compared with the general population, however it was increased amongst those taking thiopurines. We hope these findings encourage other researchers to investigate more about the drug and its potentially harmful effects."

Researchers conducted a prospective observational study to determine the trends of IBD patients exposed to thiopurines. The researchers studied 19,486 patients enrolled in the Cancers Et Surrisque Associ aux Maladies inflammatoires intestinales En France study from May 2004 through June 2005. After three years of follow up, five patients were diagnosed with incident myeloid disorders. Four of these patients had been previously exposed to thiopurines. Patients who were not receiving thiopurines during the study and those who never received these drugs did not have an increased risk of myeloid disorders.

While these findings provide strong evidence of the connection between thiopurines and myeloid disorders in IBD patients, the absolute risk to an individual patient is only 1 in 10,000. The link between IBD patients receiving thiopurines and myeloid disorders remains complex. Physicians need to balance this risk against the known benefits of thiopurines in the management of IBD.


'/>"/>
Contact: Rachel Steigerwald
media@gastro.org
301-272-1603
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Exposure to dim light at night may make breast cancers resistant to tamoxifen
2. Infant toenails reveal in utero exposure to low-level arsenic, Dartmouth study finds
3. Study: Motivational interviewing helps reduce home secondhand smoke exposure
4. BPA exposure during fetal development raises risk of precancerous prostate lesions
5. Beaumont research finds advanced CT scanners reduce patient radiation exposure
6. Exposure to TV violence related to irregular attention and brain structure
7. Does dad matter? New study looks at his environmental exposure in reproductive success
8. Early exposure to certain bacteria may protect toddlers from wheezing
9. Study links evening blue light exposure to increased hunger
10. Study of third hand nicotine from e-cigarette exposure wins NIH Addiction Science Award
11. Water pipe smoking causes significant exposure to nicotine and cancer-causing agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp ... in and around the greater Phoenix metropolitan region, is announcing a charity event ... mission of the Homeless Youth Connection is to promote community awareness of the ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... families and business owners in and around central Kansas, is joining the Youth ... youth in the region. , Headquartered in Wichita, Youth Horizons works to empower ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader ... MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that meets the ... light where and when it’s needed. , A 2’ x 4’ model ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , December 8, 2016 According to a new ... BP, Sleep, Fetal), Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type ... by MarketsandMarkets, the global market, in terms of value, is projected to ... a CAGR of 18.0% during the forecast period. ... ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  Haemonetics Corporation (NYSE: ... NextGen DMS (Donor Management System), an innovative software suite designed ... The launch of NextGen DMS 4 improves ... including: reducing the cost per liter of plasma collected, enhancing ... improve plasma center operations. ...
(Date:12/8/2016)... BEIJING , and SAN DIEGO , ... genomic services and solutions with cutting edge next-generation sequencing and ... biotechnology company; and the Genome Institute of ... (NovogeneAIT) – a new joint venture between Novogene and AITbiotech ... at Biopolis, Singapore .   ...
Breaking Medicine Technology: